Speaker:
Ashley E. Glode, PharmD, BCOP
Assistant Professor
Department of Clinical Pharmacy
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences
Aurora, Colorado
Ashley E. Glode, PharmD, BCOP has no relevant financial relationships with commercial interests to disclose.
At the completion of this activity, pharmacists, physicians, and nurses will be able to:
- Compare the pharmacology, mechanisms of action, and safety data for newly approved and emerging anticancer therapies.
- Analyze the latest data on efficacy for newly approved and pipeline anticancer therapies.
- Examine the roles of members of the oncology multidisciplinary team in the support and management of patients receiving treatment with recently approved anticancer therapies.
At the completion of this activity, pharmacy technicians will be able to:
- Describe the mechanisms of action for newly approved and emerging anticancer therapies.
- Recall indications for newly approved and pipeline anticancer therapies.
- Detail opportunities for pharmacy technicians to assist the oncology multidisciplinary team in the support and management of patients receiving treatment with recently approved anticancer therapies.
Activity Overview:
Despite challenges related to the COVID-19 pandemic throughout 2020, numerous oral oncolytics received FDA approval, and many more are under investigation with expected approvals. The oncology care team needs to stay ahead and be prepared for these important developments. Novel oral oncolytics have the potential to impact patient care for both solid and hematologic malignancies throughout the patient journey. This activity will review drug pharmacology, mechanism of action, medication dosing, and management considerations for recently approved and pipeline agents. By determining the appropriate place in therapy for oral oncolytic agents, physicians, nurses, and pharmacists can guide treatment decisions and assist in developing patient-specific management plans to optimize care for patients on these therapies.